Lower Risk MDS Per IPSS-R
Conditions
Brief summary
This is a prospective, single center, single-arm, phase 2 study. The aim of this study is to evaluate the efficacy and safety of Luspatercept for Patients with Lower-risk Myelodysplastic Syndromes (MDS).
Interventions
DRUGLuspatercept
The starting dose is 1.75mg/kg once every 3 weeks by subcutaneous injection. For rapid hemoglobin rise after 2 consecutive doses at the 1.75mg/kg starting dose, decrease the dose of Luspatercept or interrupt treatment. Otherwise, continue treatment with the dose of 1.75mg/kg once every 3 weeks.
Sponsors
Beijing Health Alliance Charitable Foundation
Institute of Hematology & Blood Diseases Hospital, China
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female age ≥ 18 years * Subject has diagnosis of MDS according to WHO classification that meets IPSS-R score ≤3.5 * Hemoglobin \< 100g/L at baseline * Refractory or intolerant to prior ESA treatment or EPO≥500U/L * ECOG performance status ≤2 * Willing and able to comply with the requirements for this study and written informed consent.
Exclusion criteria
* Platelet counts \< 50 x 10\^9/L * Previously treated with either luspatercept or sotatercept * Use any of the following prior to this study * Immunomodulatory drugs such as lenalidomide \[IMiD\] for ≥4 weeks * Immunosuppressive therapy \[IST\] for ≥4 weeks * Demethylating agents \[HMA\] ≥ 1 cycle of treatment * MDS associated with del 5q cytogenetic abnormality * Secondary MDS, i.e. MDS that is known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation for other diseases. * Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or gastrointestinal bleeding. * Prior allogeneic or autologous stem cell transplant. * Prior history of malignancies, other than MDS, unless the subject is free of the disease (including completion of any active or adjuvant treatment for prior malignancy) for ≥ 5 years. However, subjects with the following history/concurrent conditions are allowed: basal or squamous cell carcinoma of the skin, superficial bladder cancer, prostate intraepithelial neoplasia, carcinoma in situ of the cervix or other indolent tumors. * Uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment), known human immunodeficiency virus (HIV), known evidence of active infectious hepatitis B, and/or known evidence of active hepatitis C. * Clinically significant cardiac disease, including any of the follow: uncontrolled angina pectoris, myocardial infarction, unstable cardiac arrhythmias, congestive heart failure and New York Heart Association (NYHA) grade 2-4 cardiac failure. * Abnormal liver function: two consecutive examinations with an interval of ≥1 week suggest that ALT and AST are 2.5 times higher than the upper limit of normal values * Renal impairment: creatinine clearance \<60ml/min * Any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study, including clinically significant cardiac diseases, refractory hypertension, metabolic disorders and other diseases that seriously affect the function of the gastrointestinal tract. * Had a history of any psychiatric diseases, cerebrovascular disease or cognitive sequelae of head injury. * Major surgery within 8 weeks prior to this study. Subjects must be completely recovered from any previous surgery prior to this study. * Received attenuated vaccine in 4 weeks before enrollment. * Participation in another clinical trial within 4 weeks before the start of this trial. * History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the luspatercept. * Pregnant or breast-feeding patients * Patients considered to be ineligible for the study by the investigator for reasons other than the above.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of subjects achieving hematologic improvement - erythroids (HI-E) according to IWG 2006 criteria | within 12 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of subjects achieving RBC-TI according to IWG 2006 criteria | within 12 weeks | — |
| Median time to HI-E or RBC-TI | within 12 weeks | — |
| Mean change in serum ferritin | within 12 weeks | — |
| Incidence of the adverse event | within 12 weeks | Use Common Terminology Criteria for Adverse Events (CTCAE) Version 5 to assess the adverse event. |
Countries
China
Contacts
Primary ContactZhen Gao
Backup ContactJingyu Zhao
Outcome results
None listed